H G Kress1, A Baltov2, A Basiński3, F Berghea4, J Castellsague5, C Codreanu6, E Copaciu7, M A Giamberardino8, M Hakl9, L Hrazdira10, M Kokavec11, J Lejčko12, L Nachtnebl13, R Stančík14, A Švec15, T Tóth16, M V Vlaskovska17, J Woroń18. 1. a a Medical University/AKH Vienna - Dept. of Special Anaesthesia and Pain Therapy , Vienna , Austria. 2. b b Emergency Trauma Hospital 'N.I. Pirogov' -Department of Trauma Surgery , Sofia , Bulgaria. 3. c c Medical University of Gdańsk, Clinical Emergency Department of the University Clinical Center , Gdańsk , Poland. 4. d d Clinical Hospital Saint Maria, Carol Davila University of Medicine, Department of Rheumatology , Bucharest , Romania. 5. e e RTI Health Solutions International , Barcelona , Spain. 6. f f Center of Rheumatic Disease 'Dr. Ion Stoia', Carol Davila University of Medicine, Rheumatology Department , Bucharest , Romania. 7. g g University Emergency Hospital, Carol Davila University of Medicine - Anesthesia and Intensive Care Department , Bucharest , Romania. 8. h h 'G. d'Annunzio' University of Chieti-Pescara - Department of Medicine and Science of Aging , Chieti , Italy. 9. i i Masaryk University St. Ann's University Hospital - Department of Anesthesiology and Intensive Care Medicine , Brno , Czech Republic. 10. j j Faculty of Sports Studies Masaryk University - Department of Health Support , Brno , Czech Republic. 11. k k Orthopedic Department, Children's Faculty Hospital , Bratislava , Slovak Republic. 12. l l University Hospital Pilsen - Department of Anaesthesiology and Intensive Care , Plzeň , Czech Republic. 13. m m Masaryk University St. Anne's University Hospital - 1st Orthopaedics Department , Brno , Czech Republic. 14. n n Research Institute of Rheumatic Diseases in Piešťany -National Institute of Rheumatic Diseases , Piešťany , Slovak Republic. 15. o o University Hospital Bratislava - First Department of Orthopaedics and Trauma Surgery , Bratislava , Slovak Republic. 16. p p MÁV PolyClinic - Department of Rheumatology , Debrecen , Hungary. 17. q q Medical University of Sofia - Department of Pharmacology and Toxicology , Sofia , Bulgaria. 18. r r Jagellonian University College of Medicine - Department of Clinical Pharmacology and Department of Pain Treatment and Palliative Care , Kraków , Poland.
Abstract
BACKGROUND: This article summarizes the outcome from an international consensus meeting, which took place in Vienna on 4 November 2014. SCOPE: The aim of the meeting was to provide the state of the art on the pathophysiology and treatment of acute pain with special emphasis on nimesulide, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of acute pain and primary dysmenorrhea. Besides the data on the mechanisms of acute inflammatory pain and on the efficacy and safety of nimesulide in patients affected by different forms of acute pain, the clinical experience of attending experts was discussed based on selected case reports. RESULTS: The members of this consensus group recognized that nimesulide is a NSAID highly effective in the treatment of several painful situations with an acute inflammatory component including primary dysmenorrhea. Although safety concerns regarding nimesulide have emerged in recent years, both robust new epidemiological data and clinical experience confirm a positive benefit/risk profile of nimesulide in the treatment of several forms of acute pain. CONCLUSIONS: The members of this international consensus group concluded that nimesulide, when used appropriately, remains a particularly valuable and safe option for the treatment of several conditions characterized by the presence of acute inflammatory pain because of the rapid onset of the analgesic action, and the positive evidence-based benefit/risk profile.
BACKGROUND: This article summarizes the outcome from an international consensus meeting, which took place in Vienna on 4 November 2014. SCOPE: The aim of the meeting was to provide the state of the art on the pathophysiology and treatment of acute pain with special emphasis on nimesulide, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of acute pain and primary dysmenorrhea. Besides the data on the mechanisms of acute inflammatory pain and on the efficacy and safety of nimesulide in patients affected by different forms of acute pain, the clinical experience of attending experts was discussed based on selected case reports. RESULTS: The members of this consensus group recognized that nimesulide is a NSAID highly effective in the treatment of several painful situations with an acute inflammatory component including primary dysmenorrhea. Although safety concerns regarding nimesulide have emerged in recent years, both robust new epidemiological data and clinical experience confirm a positive benefit/risk profile of nimesulide in the treatment of several forms of acute pain. CONCLUSIONS: The members of this international consensus group concluded that nimesulide, when used appropriately, remains a particularly valuable and safe option for the treatment of several conditions characterized by the presence of acute inflammatory pain because of the rapid onset of the analgesic action, and the positive evidence-based benefit/risk profile.
Authors: Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker Journal: Paediatr Drugs Date: 2022-09-02 Impact factor: 3.930
Authors: R Vellucci; R Terenzi; J A Kanis; H G Kress; R D Mediati; J-Y Reginster; R Rizzoli; M L Brandi Journal: Osteoporos Int Date: 2018-04-04 Impact factor: 4.507